Clinical trials: Severe Pneumonia
COVID-19, Endotracheal Intubation
Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia
To analyze the intubation with severe covid-19 pneumonia, the infection rate of anesthesiologist after intubation, and summarizes the experience of how to avoid the infection of anesthesiologist and ensure the safety of patients…
- Trial name
- NCT04298814
- Testing
- severe covid-19 pneumonia with ET
- Where
- China
- Sponsor
- Tongji Hospital
SARS-CoV, Nutrition Disorders
Nutritional Assessment of Hospitalized Patients With COVID-19
The nutritional consequences of the infection by the SARS-CoV-2 are as follows: A severe respiratory infection induces an inflammatory syndrome and hypercatabolism, as well as an increase in energy expenditure related to…
- Trial name
- DenutCOVID (NCT04503525)
- Testing
- Nutritional assessment
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Lille Catholic University
Covid19, Severe Mental Disorder
COVID-19 Serological Testing of Patients With a Mental Disorder From the Catchment Area of the Capital Region of Denmark
The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has lately caused worldwide health problems.
- Trial name
- NCT04775407
- Testing
- blood sampling
- Where
- Denmark
- Volunteers
- 1,355 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
HIV-1-infection, SARS-CoV Infection
SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort
Prospective, observational SARS-CoV2 serological surveillance single London HIV outpatient center study using NHS participants
- Conditions
- HIV-1-infection, SARS-CoV Infection, Covid19
- Trial name
- SCAPE-HIV (NCT05067400)
- Where
- United Kingdom
- Volunteers
- 615 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of…
- Trial name
- NCT04426695
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 123 sites in United States, Brazil and 4 more
- Volunteers
- 2,252 people
- Sponsor
- Regeneron Pharmaceuticals
Covid-19
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Two recent studies have suggested that in patients with Covid19, treatment with hydroxychloroquine may shorten the duration of symptoms and improve viral clearance, an effect that appears most pronounced when combined with…
- Trial name
- NCT04358081
- Testing
- HCQ, HCQ+AZT
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Chronic, Non Malignant Pain
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
Two stage study looking at different titration schedules in patients with moderate to severe non-malignant chronic pain. Up to 80 patients at approximately 15 centers in the US to be enrolled.
- Trial name
- NCT00485225
- Testing
- EN3270
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Durect
Post COVID-19 Condition, Post-COVID-19 Syndrome
Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments
Over 500 million people have been infected with COVID-19, and to date, more than 6 million people have died. Many individuals who have recovered from COVID-19 continue to experience symptoms even after they have been "cured" of…
- Conditions
- Post COVID-19 Condition, Post-COVID-19 Syndrome, Post-COVID Syndrome, COVID-19
- Trial name
- PCS-HBOT (NCT06082518)
- Testing
- Monoplace Hyperbaric Chamber (Class III medical device).
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Sunnybrook Health Sciences Centre
Covid19, Acute Respiratory Failure
Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR)
COVID-19 pneumonia can cause severe acute hypoxemic respiratory failure. The usefulness of noninvasive respiratory support (NIRS), by means of nasal high-flow oxygen (NHFO), continuous positive airway pressure (CPAP), or…
- Conditions
- Covid19, Acute Respiratory Failure, Corona Virus Infection
- Trial name
- CATCOVID-AIR (NCT04668196)
- Testing
- High-flow nasal cannula treatment, Continuous positive airway pressure (CPAP) treatment, Noninvasive ventilation treatment
- Where
- 10 sites in Spain
- Volunteers
- 367 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Covid19
PCR Cycle Threshold Values and COVID-19 Outcomes
This is a retrospective observational study. The study will use high quality, reliable data that has already been collected for the ISARIC 4C COVID-19 study in order to analyse the relation between predictor variables (laboratory…
- Trial name
- NCT04651413
- Testing
- PCR Value
- Where
- United Kingdom
- Volunteers
- 934 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
COVID-19 Respiratory Infection, Rehabilitation
Efficacy of Respiratory Rehabilitation After COVID-19 Severe Infection
The purpose of this study is to investigate the effects of a training program in patients that have suffered a COVID infection
- Conditions
- COVID-19 Respiratory Infection, Rehabilitation, Physical Therapists
- Trial name
- COVFIS2021 (NCT05307562)
- Testing
- Interval training + analytical strength, Interval training + analytical strength and IMT
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Sars-CoV-2 Infection
Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19
Introduction: A pandemic such as the SRAS-CoV-2 (COVID-19) has a great negative socioeconomic impact with very limited therapeutic options.
- Trial name
- NCT05160779
- Testing
- Analysis of genetic polymorphisms of vasoactive peptides in COVID-19
- Where
- 2 sites in Brazil
- Volunteers
- 151 people
- Sponsor
- Leonardo Paroche de Matos
COVID-19, Burnout
Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic
Healthcare systems around the world have faced tremendous stress because of the COVID-19 pandemic. Healthcare workers (HCWs) (ie.
- Conditions
- COVID-19, Burnout, Burnout, Professional, Work-related Illness
- Trial name
- NCT05394051
- Testing
- Positive Affect Regulation sKills (PARK)
- Where
- United States
- Volunteers
- 555 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Sepsis, Severe Community-acquired Pneumonia (sCAP)
Molecular Biomarkers for Sepsis
This multi-center observational case-control study in Intensive Care Unit (ICU) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP) -associated sepsis at an earlier stage and…
- Conditions
- Sepsis, Severe Community-acquired Pneumonia (sCAP), Infection, Bacterial
- Trial name
- NCT04280354
- Testing
- compare data patterns by data-driven algorithms to determine sepsis, compare data patterns by data-driven algorithms to predict sepsis-related mortality
- Where
- 15 sites in Switzerland
- Volunteers
- 3 people
- Sponsor
- University Hospital, Basel, Switzerland
VAP - Ventilator Associated Pneumonia, Antibiotic
EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)
The objective of the study is to determine whether rapid multiplex PCR testing of respiratory samples can reduce exposure to broad-spectrum antibiotics in intensive care unit patients with suspected or confirmed…
- Conditions
- VAP - Ventilator Associated Pneumonia, Antibiotic, Antibiotic Stewardship, Antibiotic Prescribing for Acute Respiratory-tract Infections
- Trial name
- EARLY ADAPT (NCT07267624)
- Testing
- PCR multiplex BioFire Pneumonia plus
- Where
- 5 sites in Switzerland
- Volunteers
- 170 people
- Sponsor
- University Hospital, Geneva
Covid19, Ventilator Associated Pneumonia
Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:
A Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation.
- Conditions
- Covid19, Ventilator Associated Pneumonia, Nosocomial Pneumonia
- Trial name
- COVAP (NCT04488510)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19 Induced Pneumonia, Covid19
Asunercept in Patients With Severe COVID-19
This is an open-label, randomized, phase II study with the main objective to investigate the effectiveness and safety of an investigational drug (APG101; International Nonproprietary Name: asunercept) in patients with severe…
- Trial name
- ASUNCTIS (NCT04535674)
- Testing
- Asunercept
- Where
- 13 sites in Russia, Spain
- Volunteers
- 438 people
- Sponsor
- Apogenix AG
COVID-19 Infection
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone…
- Trial name
- NCT07013474
- Testing
- ibuzatrelvir, remdesivir
- Where
- 159 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.